Column-based positive selection of human CD66b⁺ granulocytes, or depletion of CD66b⁺ cells — purity up to 95%.
Anti-human CD66b nanobeads enrich CD66b⁺ granulocytes from human peripheral blood, or deplete them from mixed samples. CD66b (CD67, CGM6, NCA-95) is a 95–100 kD GPI-anchored glycoprotein of the CEA-like subfamily, expressed on granulocytes. In column-based positive selection the CD66b⁺ cells are retained in the column while the remainder flows through; the flow-through is the CD66b-depleted fraction. Purity reaches up to 95% on human peripheral blood.
| Catalogue | Size | List price | Promo price | Manual | COA |
|---|---|---|---|---|---|
| PH066BL | 2 mL, for 1e+9 cells | ¥4000 | ¥2400 | Search | |
| PH066BM | 1 mL, for 5e+8 cells | ¥2500 | ¥1500 | Search | |
| PH066BS | 0.2 mL, for 1e+8 cells | ¥700 | ¥480 | Search |
| Parameter | Value |
|---|---|
| Target | CD66b (CEACAM8); also CD67, CGM6, NCA-95 |
| Molecular weight | 95–100 kD, GPI-anchored glycoprotein |
| Antibody format | anti-human CD66b directly conjugated to nanobeads |
| Buffer | PBS, 0.1% BSA |
| Storage | 4 °C, do not freeze |
| Recommended dose | Lysed blood: 20 µL per 1×10⁷ cells; whole blood: 50 µL per mL |
| Incubation | 4 °C, 15 min |
| Purity | up to 95% (human peripheral blood) |
| Manual | v26.01 |
Cells were labelled with FITC anti-human CD66b and APC anti-human CD45 before and after separation, at 20 µL beads per 1×10⁷ cells.
| Sample | Before | After |
|---|---|---|
| Lysed peripheral blood (CD66b⁺) | 55.7% | 99.3% |
| Whole blood, no lysis (CD45⁺ / CD66b⁺ within gate) | CD45⁺ 15%, CD66b⁺ 88.0% | CD45⁺ 93.5%, CD66b⁺ 99.9% |
Data are a single experiment from manual v26.01 and were not repeated in-house. No cell counts were provided, so yield and recovery are not reported.
CD66b (also CD67, CGM6, NCA-95) is a 95-100 kD glycosylphosphatidylinositol (GPI)-anchored glycoprotein and a member of the carcinoembryonic antigen (CEA)-like subfamily of the immunoglobulin superfamily. It is expressed on granulocytes and participates in heterophilic adhesion with CD66c. Positive selection therefore yields a granulocyte population dominated by neutrophils.
The three markers are molecularly distinct. CD66b is a GPI-anchored CEA-family glycoprotein; CD15 (Lewis X) is a fucosylated carbohydrate antigen also enriched on granulocytes; CD16 is Fc gamma receptor III, a transmembrane protein present on both granulocytes and NK cells. CD66b does not depend on Fc receptors, so it is not affected by antibody Fc binding. Validate your own gating combination on your instrument before fixing it.
Yes. The manual gives two protocols. The lysed-blood protocol uses 11 steps at 20 uL beads per 1x10^7 cells with a 15 min incubation at 4 C. The whole-blood protocol uses 6 steps: add 50 uL beads per 1 mL of peripheral blood, incubate 15 min at 4 C and load onto a whole-blood column, with no lysis step.
Choose by total and labelled cell numbers. The M column is rated for fewer than 1x10^7 labelled cells and fewer than 2x10^8 total cells with magnet M1/M8 (500 uL equilibration, 3 x 500 uL wash). The L column is rated for fewer than 1x10^8 labelled cells and fewer than 2x10^9 total cells with magnet L1/L4 (3 mL equilibration, 3 x 3 mL wash). Split the sample across columns above these limits.
Yes. CD66b⁺ cells are retained in the column and the flow-through is the CD66b-depleted fraction (steps 8-9 of the manual). Removing residual granulocytes from PBMC or lysed whole blood this way is gentler than repeated red-cell lysis.
Tell us your cell type, sample source and downstream assay — we will suggest an isolation route, a culture condition and the matching catalogue numbers.